Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound ...

Eli Lilly (LLY), the pharma giant that produces the popular weight-loss drug Zepbound, said it plans to test the blockbuster ...

It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...

Eli Lilly (LLY) has announced it will make lower-priced, single-dose vials of its popular weight-loss treatment Zepound ...

Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.

Eli Lilly ( LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug Zepbound.

Ro announced earlier that it is working with Eli Lilly (LLY) and Company to streamline access to Zepbound single-dose vials for Ro patients ...

"Offering Zepbound single-dose vials…through another platform to LillyDirect will help ensure broader availability of ...

For a drug that has been on the market for only a year, Eli Lilly and Co.’s anti-obesity treatment Zepbound has quickly made a huge name for itself, racking up more than $3 billion in sales and ...

BofA analyst Allen Lutz notes Ro Health, a direct competitor to Hims & Hers (HIMS), announced that the company is working with Eli Lilly ...

Tirzepatide had received approval in a single-dose prefilled pen format in January 2024 for use as an adjunct to diet and ...